GlaxoSmithKline has signed on Activiomics to investigate inflammatory signaling mechanisms. The firm was spun out of Barts and The London School of Medicine and Dentistry at Queen Mary University of London based on the development of a mass spectrometry method to analyze and interpret cell-signaling pathways.

The deal, which marks the first commercial agreement for Activiomics, was inked through GSK’s Respiratory Centre of Excellence for Drug Discovery. Activiomics reports that its Tiquas (targeted in-depth quantification of cell signaling) is quantitative, antibody-free, label-free, and applicable to any cell or tissue sample. This is of significant benefit in the drug development cycle, aiding clinical trial candidate selection and biomarker discovery, thereby reducing development times.








This site uses Akismet to reduce spam. Learn how your comment data is processed.